A PHASE 1B STUDY OF PF-05082566 IN COMBINATION WITH MOGAMULIZUMAB (KW-0761) IN PATIENTS WITH ADVANCED SOLID TUMORS
Phase of Trial: Phase I
Latest Information Update: 11 Jul 2019
Price : $35 *
At a glance
- Drugs Mogamulizumab (Primary) ; Utomilumab (Primary)
- Indications Bladder cancer; Colorectal cancer; Head and neck cancer; Non-small cell lung cancer; Ovarian cancer; Solid tumours; Squamous cell cancer
- Focus Adverse reactions
- Sponsors Pfizer
- 24 Apr 2018 Status changed from recruiting to discontinued due to marginal efficacy and change in sponsor prioritization. The combination had a manageable safety profile.
- 27 Oct 2017 Planned End Date changed from 1 Jan 2018 to 1 Oct 2017.
- 28 Sep 2017 Planned End Date changed from 14 Sep 2017 to 1 Jan 2018.